
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $36.00. Matthew Caufield has given his Buy
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | 10.23 | -0.61 | -5.63% |
| Name | Price | % Change | |
|---|---|---|---|
| $10.23 | -5.63% |

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $36.00. Matthew Caufield has given his Buy

4D Molecular Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on the stock and has

Reports Q3 revenue $4.15M, consensus $3.1M. “Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of

4D Molecular Therapeutics, Inc. (FDMT) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect 4D Molecular Therapeutics, Inc. to post earnings of -$1.05

4D Molecular Therapeutics, Inc. ($FDMT) announced an update on their ongoing clinical study. The Phase 3 4SIGHT study tests 4D-150 against Eylea in adults with diabetic macular edema, a major

BofA raised the firm’s price target on 4D Molecular (FDMT) to $33 from $29 and keeps a Buy rating on the shares after the company reported two-year data from the

Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degeneration

4D Molecular Therapeutics ( ($FDMT) ) just unveiled an update. On September 28, 2026, 4D Molecular Therapeutics reported that it has enrolled the first patients across multiple global sites in

4D Molecular (FDMT) Therapeutics announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular

Meeting to be held on September 28 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| hold | Reiterated | Oct 21, 2026 | ||||
| buy | Reiterated | Oct 21, 2026 | ||||
| buy | Reiterated | Oct 19, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 | ||||
| buy | Reiterated | Oct 6, 2026 | ||||
| buy | Reiterated | Jul 20, 2026 | ||||
| buy | Initiated | Mar 30, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027TBA | $604.39M | $-1.08 | $5.51M | 0.16 | -3.67 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.